Hemophilia A

New England CEPAC

The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of emicizumab (Genentech/Roche), a monoclonal antibody currently under review by the FDA for prevention of bleeding in patients who have hemophilia A with coagulation factor VIII inhibitors. Factor VIII is the clotting protein that is deficient in hemophilia A, and inhibitors interfere with factor replacement therapy. An FDA approval decision is expected in the first quarter of 2018.

Associated Meetings

March 29, 2018 10am-4pm EST

Boston, MA

The New England CEPAC will convene to review the comparative clinical effectiveness and value of emicizumab for treatment of hemophilia A.


Key Dates

Associated Materials

08/11/2017

08/11/2017 – 09/06/2017

09/11/2017

09/11/2017 – 09/29/2017

10/10/2017

11/21/2017

11/21/2017

01/26/2018
Draft Voting Questions

01/26/2018
Draft Evidence Report

01/26/2018 – 02/23/2018
Public Comments

03/15/2018
Response to Comments

03/15/2018
Evidence Report

03/15/2018
Revised Voting Questions

03/29/2018
Meeting Agenda

03/29/2018
Evidence Presentation

04/12/2018
Final Evidence Report and Meeting Summary

04/12/2018
Report-at-a-Glance